Related Experiment Video
Updated: Aug 18, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
[Clinical studies on norfloxacin in the field of pediatrics]
Insights
Norfloxacin (NFLX) tablets showed a 90% efficacy rate in treating bacterial infections in children aged 6 and older. The study found no adverse effects, suggesting NFLX is a potentially safe and effective treatment option.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Clinical Microbiology
Context:
- Norfloxacin (AM-715) is a new quinolone antibiotic.
- Bacterial infections are common in pediatric populations.
Purpose:
- To evaluate the clinical efficacy and safety of norfloxacin tablets in children.
- To assess the bacteriological eradication rates of norfloxacin.
Summary:
- Ten pediatric patients with various infections (tonsillitis, pharyngitis, bronchitis, enteritis) received norfloxacin (7.0-14.8 mg/kg) thrice daily for 6-8 days.
- An overall clinical efficacy rate of 90% was observed (8 excellent, 1 good, 1 fair).
- Bacteriological eradication was achieved in 66.7% of cases, with no adverse reactions or abnormal laboratory findings.
Impact:
- Norfloxacin demonstrates potential as a safe and effective treatment for bacterial infections in children aged 6 and older.
- The study supports the use of this new quinolone in pediatric infectious disease management.
Abstract:
We studied clinical effects of norfloxacin (NFLX, AM-715) tablets. The results we found are summarized as follows: 1. Ten patients with 5 diseases were medicated with 7.0-14.8 mg/kg of the drug 3 times daily for 6-8 days. They consisted of one-each with tonsillitis, pharyngitis, bronchitis, 4 with Campylobacter enteritis, 3 with other enteritis. Clinical responses to the treatment were excellent in 8, good in 1 and fair in 1, with an efficacy rate of 90%. Bacteriologically, of 9 isolates for which changes in populations were followed, 6 were eradicated and 3 remained unchanged, with an eradication rate of 66.7%. 2. No. adverse reactions nor abnormal laboratory test values attributable to the drug were observed. 3. These results suggest that this new quinolone drug may be useful, against bacterial infections in children 6 years and older.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Urine Studies II: Urine Culture and Sensitivity Test

